Meta tags:
description=Stay updated with the latest news, insights, and analysis from FirstWord PHARMA. FirstWord PHARMA provides comprehensive coverage of key developments and trends.;

Headings (most frequently used words):

firstword, top, stories, conference, news, insight, analysis, views,

Text of the page (most frequently used words):
the (16), ago (11), and (10), for (9), data (7), multiple (7), clinical (7), 2026 (5), sclerosis (5), its (4), study (4), from (4), new (3), #firstword (3), views (3), first (3), will (3), pharma (3), novel (3), positive (3), novartis (3), with (3), mstoronto2026 (3), zenas (3), company (3), platform (3), inhibitor (3), oral (3), spotlight (2), genmab (2), abbvie (2), line (2), dlbcl (2), analysis (2), oct (2), nordic (2), inc (2), subsidiary (2), sever (2), life (2), sciences (2), feature (2), lacrifill (2), canalicular (2), gel (2), therapy (2), ocular (2), surface (2), control (2), during (2), patient (2), late (2), breaking (2), phase (2), iii (2), remodel (2), safety (2), profile (2), remibrutinib (2), portfolio (2), biopharma (2), trial (2), progressive (2), other (2), one (2), year (2), results (2), stiff (2), person (2), syndrome (2), presentation (2), potential (2), fabp5 (2), europe (2), news (2), biotech (2), sale (2), cell (2), modulator (2), court (2), keytruda (2), second (2), breast (2), cancer (2), fda (2), chronic (2), loading, 1140, avenue, americas, 14th, floor, york, 10036, all, rights, reserved, deliver, promise, bispecifics, front, physician, depth, hae, prophylactics, take, aim, entrenched, takhzyro, shionogi, rare, disease, blueprint, takes, shape, vital, signs, shots, fired, jersey, latest, layoff, tallies, kol, preview, epkinly, may, bispecific, but, best, insight, doylestown, prnewswire, through, share, experience, aao, trials, show, efficacy, rms, hold, virtual, investor, event, highlighting, remibr, advances, innovation, broad, waltham, mass, globe, newswire, nasdaq, zbio, stage, global, biopharmaceutical, advancing, therapies, patients, announces, upcoming, presentations, orelabrutinib, relapsing, remitting, designs, full, kysa, registrational, reported, demonstrating, sustained, benefit, well, tolerated, high, grade, crs, kyverna, therapeutics, present, 31m, art26, highlight, inhibition, across, indicationsbio, provides, key, advance, ongoing, artelo, biosciences, selected, ever, bio, showcase, progress, expanding, conference, 20h, pursuing, merger, strategic, deal, caribou, cans, car, cuts, staff, studies, mpt, 062, which, stems, advanced, covalent, exploration, ace, are, expected, begin, next, matchpoint, targets, 2027, lead, following, 150m, raise, dutch, patent, hague, determined, that, subcutaneous, formulation, pembrolizumab, infringes, halozyme, patents, around, mdase, technology, orders, merck, halt, countries, higher, dose, solengepras, significantly, reduced, average, daily, off, time, compared, placebo, week, cerevance, drug, meets, main, goal, parkinson, tyrosine, kinase, was, previously, approved, treatment, metastatic, her2, clears, pfizer, tukysa, frontline, maintenance, setting, top, stories, nod, symptomatic, dermographism, adds, btk, earlier, approval, spontaneous, urticaria, rhapsido, wins, label, expansion, form, hives, you, need, enable, javascript, run, this, app, industry,

Text of the page (random words):
industry news and analysis firstword pharma you need to enable javascript to run this app firstword novartis rhapsido wins us label expansion for second form of chronic hives the fda nod for symptomatic dermographism adds to the btk inhibitor s earlier approval in chronic spontaneous urticaria 2h ago top stories fda clears pfizer s tukysa for frontline maintenance setting in breast cancer the oral tyrosine kinase inhibitor was previously approved as a second line treatment for metastatic her2 positive breast cancer 1h ago cerevance s oral drug meets main goal of phase iii parkinson s study the higher dose of solengepras significantly reduced the average daily off time compared with placebo at week 12 6h ago court orders merck co to halt sale of keytruda sc in multiple eu countries the dutch patent court of the hague determined that the subcutaneous sc formulation of keytruda pembrolizumab infringes one of halozyme s patents around its mdase technology 7h ago matchpoint targets 2027 clinical study of lead t cell modulator following 150m raise clinical studies of the oral t cell modulator mpt 062 which stems from the biotech s advanced covalent exploration ace platform are expected to begin next year 8h ago caribou cans car ts cuts staff the biotech is pursuing a sale merger or other strategic deal 20h ago conference news artelo biosciences selected for its first ever company presentation at bio europe 2026 to showcase clinical progress and expanding potential of its novel fabp5 inhibitor platform presentation to feature results from first clinical study of art26 12 and highlight the potential of fabp5 inhibition across multiple indicationsbio europe provides a key platform to advance ongoing d 31m ago kyverna therapeutics to present positive data in stiff person syndrome and progressive multiple sclerosis at mstoronto2026 full one year results from the kysa 8 registrational trial in stiff person syndrome to be reported demonstrating sustained clinical benefit and a well tolerated safety profile with no high grade crs 2h ago zenas biopharma announces upcoming presentations of orelabrutinib data in relapsing remitting multiple sclerosis clinical trial designs in progressive multiple sclerosis and other multiple sclerosis portfolio data at mstoronto2026 waltham mass oct 07 2026 globe newswire zenas biopharma inc zenas or the company nasdaq zbio a clinical stage global biopharmaceutical company advancing therapies for patients li 2h ago novartis advances multiple sclerosis innovation with late breaking remibrutinib and broad portfolio data at mstoronto2026 late breaking data from positive phase iii remodel 1 2 trials will show efficacy and safety profile of remibrutinib in rms novartis to hold virtual investor event highlighting remodel data and remibr 2h ago sever life sciences through its subsidiary nordic pharma to share patient data and patient experience study for lacrifill canalicular gel a novel therapy for ocular surface control during aao 2026 doylestown pa oct 7 2026 prnewswire nordic pharma inc a subsidiary of sever life sciences b v will feature lacrifill canalicular gel a novel therapy for ocular surface control during 3h ago insight analysis views kol views preview genmab abbvie s epkinly may be first bispecific in 1l dlbcl but will it be best vital signs shots fired at new jersey in latest layoff tallies spotlight on shionogi s rare disease blueprint takes shape physician views in depth new hae prophylactics take aim at entrenched takhzyro spotlight on genmab abbvie deliver on the promise of bispecifics in front line dlbcl 2026 firstword all rights reserved 1140 avenue of the americas 14th floor new york ny 10036 loading